Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Comorbidity in HPV+ and HPV- oropharyngeal cancer patients: A population-based, case-control study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Upfront PET/CT affects management decisions in patients with recurrent head and neck squamous cell carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. MicroRNA-based classifiers for diagnosis of oral cavity squamous cell carcinoma in tissue and plasma

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Association between head and neck cancer and sexually transmitted diseases: a Danish nationwide, case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Circulating tumour DNA alterations as biomarkers for head and neck cancer: a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  3. The current epidemic of HPV-associated oropharyngeal cancer: An 18-year Danish population-based study with 2,169 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Trends of ankyloglossia and lingual frenotomy in hospital settings among children in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVES: Comorbid conditions impact outcome for patients treated for oropharyngeal squamous cell carcinoma (OPSCC) and serve as competing risk factors for death. The purpose of this study was to examine differences in comorbidities in patients with OPSCC and known HPV-DNA.

MATERIAL AND METHODS: We included patients diagnosed with OPSCC in Eastern Denmark in 2000-2014. Patients were linked to the Danish National Patient Register to identify comorbidities based on the Charlson Comorbidity Index (CCI) at time of diagnosis and following cancer treatment. Patients were age-and sex-matched in a 1:10 ratio with a reference group and stratified according to HPV-status.

RESULTS: In total 1,499 patients (55.0% HPV+) and 14,990 controls were included. Significantly more HPV+ patients had no comorbidities compared to HPV- patients at time of diagnosis (RR: 1.5 (1.3;1.6), n = HPV+: 522, HPV-: 302) and following treatment (RR 1.5 (1.4;1.6), n = HPV+: 342, HPV-: 142). Most prevalent comorbidity was malignancy not including OPSCCs. HPV+ patients had an increased risk of having AIDS before their OPSCC diagnosis compared to the reference population (OR: 4.8 (1.8;12.9)). HPV- patients had increased risk of multiple comorbidities including cerebrovascular disease (OR: 1.9 (1.4;2.5)), peripheral vascular disease (OR: 1.7 (1.9;3.7)), dementia (OR: 2.9 (1.4;5.8)), ulcer disease (OR: 2.6 (1.9;3.5)), liver disease, mild (OR: 9.5 (7.0;13.0)) and severe (OR: 13.9 (5.8;22.8)).

CONCLUSION: This study showed that HPV- patients had more comorbidities than HPV+ patients at the diagnosis time and following treatment. Irrespective of HPV-status, OPSCC patients had a significant increased risk of (secondary) malignancy compared to the reference population.

Original languageEnglish
JournalOral Oncology
Volume96
Pages (from-to)1-6
Number of pages6
ISSN1368-8375
DOIs
Publication statusPublished - 1 Sep 2019

    Research areas

  • Charlson Comorbidity Index (CCI), Comorbidity, Human papillomavirus, Oropharyngeal cancer

ID: 58346344